Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy counter. Then IBSRELA, its drug for irritable bowel syndrome with constipation, started filling prescriptions at scale, and revenue grew from a standing start to hundreds of millions of dollars. That kind of trajectory earns a company a certain kind of faith from investors. What the August 2026 filings show is that the faith is being tested, and the math and the mood are pulling in opposite directions.
The math, meaning what the filed numbers actually say, shows a business still growing. The mood, meaning what the market is currently paying for that growth, has turned sharply skeptical. The stock has lost more than half its value over the past six months and sits well off its yearly high. That gap between a growing revenue line and a collapsing share price is the story.
What matters here
Revenue has compounded from almost nothing to more than $400 million in three years, and the most recent quarter showed strong double-digit year-over-year growth. But the company cut its full-year guidance for its lead drug by roughly $60 million at the midpoint, and the stock is priced at two times annual sales, against a decade median of nearly 17 times. Those two readings cannot both be right, and the guidance cut is the reason the gap opened.
A year of compounding, then a stumble
The 10-K for fiscal year 2025 shows total revenue of $407 million, up 22% from the prior year. That is a business that has grown roughly fifty-fold in three years, which is the kind of number that sounds made up until you see the filing. The catch is that the company still posted a net loss: spending exceeded revenue by about fifteen cents on every dollar earned in 2025. Growing fast while losing money is not unusual for a drug company building out its commercial infrastructure, but it means every dollar of revenue growth has to be weighed against what it costs to generate.
Then came the second quarter of 2026. The 10-Q for the quarter ended June 30, 2026 shows product revenue of $118.1 million, up 31% from the same quarter a year earlier. That is genuinely strong. But the company also revised its full-year IBSRELA revenue guidance down to a range roughly $60 million below its original midpoint. For a business this concentrated, a guidance cut of that size is not a footnote.
One drug, one departure, one question
Ardelyx’s entire commercial story rests on IBSRELA. There is no second approved product cushioning the blow if IBSRELA disappoints. So when the guidance came down, the market did what markets do with concentrated bets: it repriced sharply. The price-to-sales ratio now sits at 2.0 times, per our data, against a decade median of 16.6 times. A ratio that low either means the market sees something structurally broken, or it means the guidance cut has been more than fully absorbed into the price. The data cannot tell us which.
What the filings can tell us is that the commercial leadership changed at the same moment. An 8-K filed August 17, 2026 disclosed that Eric Foster, the Chief Commercial Officer, resigned effective August 28, 2026. A CCO departure in the same month as a major guidance cut is a coincidence the market is unlikely to ignore. Whether the two events share a cause, or whether Foster simply found a better opportunity, the filing does not say, and we won’t speculate beyond what’s disclosed.
What compounds here
The word “compounds” has two meanings for Ardelyx right now. The first is financial: losses compound when a single-product business misses its own forecast, because every analyst model built on the old guidance has to be rebuilt from scratch. The second is structural: the risks compound because concentration in one drug, one commercial leader now departed, and one guidance revision all land in the same quarter.
The revenue trajectory from 2022 through 2025 is real and filed. A business that has grown roughly fifty-fold in three years has demonstrated that IBSRELA can find patients. The question the August filings leave open is whether the growth rate that justified a much higher valuation is still intact, or whether the guidance cut is the first signal of a plateau. The filings show the former trajectory clearly. They leave the latter question unanswered.
Reading the numbers
- $407 million, FY2025 revenue. What it is: total product sales for the year ended December 31, 2025, per the annual 10-K. What it means: the company has built a real commercial business from near-zero in three years. In everyday terms: a business that was earning roughly the price of a modest house per year in 2020 is now earning the equivalent of a mid-sized regional hospital’s annual budget.
- Negative 15%, net margin for FY2025. What it is: for every dollar of revenue, the company spent $1.15, per our data computed from the 10-K. What it means: growth is still costing more than it returns. In everyday terms: a household earning $100,000 a year but spending $115,000 is building something, but it needs the spending to slow before the math works.
- $118.1 million, Q2 2026 revenue, up 31%. What it is: product revenue for the three months ended June 30, 2026, per the 10-Q. What it means: the drug is still growing. In everyday terms: if a shop was selling 100 units a day last summer, it’s selling 131 now.
- $350 to $370 million, revised full-year 2026 IBSRELA guidance. What it is: the company’s own forecast for its lead drug’s annual sales, revised down from $410 to $430 million, per the August 2026 8-K. What it means: the company expects the second half of 2026 to be materially softer than the first half implied. The cut is roughly 15% below the original midpoint.
- 2.0 times price-to-sales, versus a decade median of 16.6 times. What it is: the price-to-sales ratio is what the market pays for each dollar of annual revenue; 2.0 means investors are paying $2 for every $1 of sales. The decade median of 16.6 is what they paid on average over the past ten years, per our data. What it means: the market has repriced this business to its lowest relative valuation in a decade. In everyday terms: a shop that used to sell for 17 times its annual takings is now priced at 2 times, which either means the takings are expected to fall sharply or the price has overshot.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Ardelyx 8-K filings, August 2026 (StockTitan)
